Comparison Effect of Prescription Drugs on the Occurrence and the Number of Attacks in Patients with Multiple Sclerosis

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Epidemiology and Biostatistics AND Student Research Committee, School of Public Health, Shahrekord University of Medical Sciences, Shahrekord, Iran

2 Professor, Isfahan Neurosciences Research Center, Alzahra Research Complex, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Social Determinants of Health Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

4 Assistant Professor, Department of Epidemiology and Biostatistics, School of Public Health, Shahrekord University of Medical Sciences, Shahrekord, Iran

5 Student of Medicine, Student Research Committee, School of Medicine AND Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Treatment has a major effect on attacks in patients with multiple sclerosis (MS). This study aimed to determine the effect of the type of used drug on occurrence and number of attacks in patients with multiple sclerosis.Methods: In this cross-sectional study, 1815 patients with multiple sclerosis referred to Ayatollah Kashani hospital in Isfahan, Iran, whose information was recorded in iMED software and followed at least for 34 months, were included. The effect of the type of drug on occurrence and number of attacks was determined using Negative Binomial Hurdle model by R software.Findings: The type of drug had a significant effect on the occurrence of attack; so that, compared to interferon beta-1a (muscle), interferon beta-1a (subcutaneous), fingolimod, glatiramer acetate and azathioprine were less effective, especially for relapsing-remitting types. Interferon beta-1b and glatiramer acetate had more and less effective on the occurrence of the attack in women and men, respectively. In women, fingolimod drugs, glatiramer acetate, and azathioprine had less effect on the number of attacks, respectively. The effect of age was significant on the occurrence and number of attacks in men and women, and both the recurrence and progressive clinical course.Conclusion: Younger patients had more occurrences of attacks. Interferon beta-1a (muscle) has a better performance than other drugs in reducing occurrence of attacks. In women, patients taking interferon beta-1b had fewer attacks compared to patients taking interferon beta-1a (muscle). In men, patients taking interferon beta-1a (muscle) had fewer attacks than those taking glatiramer acetate.

Keywords

References

  1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372(9648): 1502-17.
  2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46(4): 907-11.
  3. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: A geographically based study 9: Observations on the progressive phase of the disease. Brain 2006; 129(Pt 3): 584-94.
  4. Vosoughi R, Freedman MS. Therapy of MS. Clin Neurol Neurosurg 2010; 112(5): 365-85.
  5. Nikfar S, Rahimi R, Abdollahi M. A meta-analysis of the efficacy and tolerability of interferon-beta in multiple sclerosis, overall and by drug and disease type. Clin Ther 2010; 32(11): 1871-88.
  6. Goodin DS, Frohman EM, Garmany GP, Jr., Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58(2): 169-78.
  7. Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, et al. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. J Neurol Sci 2004; 222(1-2): 13-9.
  8. Kunze AM, Gunderson BW, Gleason PP, Heaton AH, Johnson SV. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007. J Manag Care Pharm 2007; 13(9): 799-806.
  9. Palesh M, Jonsson PM, Jamshidi H, Wettermark B, Tomson G, Fredrikson S. Diffusion of interferon beta in Iran and its utilization in Tehran. Pharmacoepidemiol Drug Saf 2008; 17(9): 934-41.
  10. Neelon B, O'Malley AJ, Smith VA. Modeling zero-modified count and semicontinuous data in health services research Part 1: Background and overview. Stat Med 2016; 35(27): 5070-93.
  11. Chitsaz A, Ashtari F. Comparison of therapeutic effect of Cinnovex and Avonex in multiple sclerosis. Proceedings of the 6th International Iranian Congress of MS; 2009 Oct 15-16; Tabriz, Iran. [In Persian].
  12. Iranmanesh F, Vakilian A. Comparison of Cinnovex, Avonex, and Rebif in treatment of relapsingremitting multiple sclerosis. Proceedings of the 17th International Congress of Neurology and Clinical Electrophysiology of Iran; 2010 May 25-28; Tehran, Iran. [In Persian].
  13. Mazdeh M, Afzali S, Jaafari MR. The therapeutic effect of Avonex, Rebif and Betaferon on EDSS and relapse in multiple sclerosis: A comparative study. Acta Med Iran 2010; 48(2): 83-8.
  14. Wu X, Dastidar P, Kuusisto H, Ukkonen M, Huhtala H, Elovaara I. Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS. Acta Neurol Scand 2005; 112(4): 242-7.
Journal of Isfahan Medical School
Volume 35, Issue 454 - Serial Number 454
September and October 2018
Pages 1557-1563

Files

History

  • Receive Date: 16 September 2017
  • Revise Date: 27 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics